SEC Form 4 · accession 0001193125-26-382412
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dawn Svoronos
Director
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 8:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Sep 1, 2026 | M | 5,144 | $8.15 | A | 31,373 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.15 | Sep 1, 2026 | M | 5,144 | D | — | Sep 26, 2026 | Common Shares | 5,144 | 0 | D |
Explanation of responses
- F1The shares subject to the option are fully vested and exercisable.